eFFECTOR Therapeutics Inc R&D Day Transcript
Good afternoon, and thank you for joining the eFFECTOR investor event. (Operator Instructions) As a reminder, this event is being recorded and a replay will be made available on the eFFECTOR website following the conclusion of the call. I would now like to turn the call over to your host, Steve Worland, President and Chief Executive Officer. Please go ahead, sir.
Thank you, Sarah, and thank you, everybody, for joining us today for our R&D event. We're really excited to present our information and our assessment of the market opportunities. Just to remind you, we will make some forward-looking statements, so I encourage you to look to our filings with the SEC.
For the agenda today, I'll do a very brief company introduction. And then for both tomi and zota, we'll do a analysis of the unmet medical need and the opportunities there, brief non-clinical overview, and then the clinical overview by Dr. Warner. With regard to zotatifin, we're fortunate to have Dr. Kevin Kalinsky from Emory join
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |